Discussion
toxicity, MDS, t-MN, AML, therapy-related myeloid neoplasms
DISEASE PROGRESSION, AML
In this analysis of a phase I/II study involving 40 patients with progressive (i.e., with documented disease progression according to RECIST version 1.1, under prior anti-tumour therapy, within the past 6 months prior to study entry), previously treated, SSTR-positive NETs, [[Here, no renal toxicity was observed, consistent with other studies of Investigators identified therapy-related myeloid neoplasms (t-MN) in the form of MDS and AML in two (5.0%) patients in this trial. This finding is comparable to other studies of PRRT performed in patients with NETs [Here, the AML diagnosis involved a patient previously treated with chemotherapy and TACE, and occurred only 1.5 months after the first [[The present study has limitations common to all phase I/II trials, including the small sample size, inconsistent treatment protocols, heterogeneity of the study population, and its non-randomised nature. Despite this, we show that PRRT with [